INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 41h ago
HOUSE PTR1h ago
SEC 13F1h ago
ROBINHOOD CHAIN1h ago
Public company

VERAVera Therapeutics, Inc.

CIK 0001831828

EDGAR filingsOpen in network
Disclosed transactions32
Buys / sells0 / 11
Max Insider Score29
Connections9with evidence

VERA · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
8
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$685K
18.5K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2834 · Pharmaceutical Preparations · Nov 4, 2026
  • ← Insider ofevidence
    Hall KimballDirector · May 26, 2026
  • ← Insider ofevidence
    Wright-Mitchell JaneChief Legal Officer · Mar 25, 2026
  • ← Insider ofevidence
    Turner William D.Chief Regulatory Officer · Feb 6, 2026
0
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Option exercise · 10b5-1 plan
M
$54K
18.5K sh
Sep 15, 2026
Sep 17, 2026
traded Sep 15, 2026
+2d
SEC FORM 4

Evidence

0
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
18.5K sh
Sep 15, 2026Sep 17, 2026
traded Sep 15, 2026
+2dSEC FORM 4

Evidence

13
YR
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
VERAVera Therapeutics, Inc.
Option exercise
M$20K
5,000 sh
Sep 11, 2026Sep 14, 2026
traded Sep 11, 2026
+3dSEC FORM 4

Evidence

13
YR
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
VERAVera Therapeutics, Inc.
Option exercise
M—
5,000 sh
Sep 11, 2026Sep 14, 2026
traded Sep 11, 2026
+3dSEC FORM 4

Evidence

8
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$650K
18.5K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

0
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Option exercise · 10b5-1 plan
M$54K
18.5K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

0
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Option exercise · 10b5-1 plan
M—
18.5K sh
Sep 2, 2026Sep 4, 2026
traded Sep 2, 2026
+2dSEC FORM 4

Evidence

1
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$3,382
88 sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

11
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$698K
18.4K sh
Jun 23, 2026Jun 24, 2026
traded Jun 23, 2026
+1dSEC FORM 4

Evidence

15
HK
Hall KimballDirector
VERAVera Therapeutics, Inc.
Grant or award
A—
17.1K sh
May 21, 2026May 26, 2026
traded May 21, 2026
+5dSEC FORM 4

Evidence

11
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$521K
14.2K sh
May 12, 2026May 13, 2026
traded May 12, 2026
+1dSEC FORM 4

Evidence

4
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$159K
4,281 sh
May 12, 2026May 13, 2026
traded May 12, 2026
+1dSEC FORM 4

Evidence

11
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$353K
7,921 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

15
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$617K
14.1K sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

5
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Open-market sale · 10b5-1 plan
SELL$41K
900 sh
Apr 14, 2026Apr 15, 2026
traded Apr 14, 2026
+1dSEC FORM 4

Evidence

9
WJ
Wright-Mitchell JaneChief Legal Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
56.9K sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC FORM 4

Evidence

9
WJ
Wright-Mitchell JaneChief Legal Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
42.4K sh
Mar 23, 2026Mar 25, 2026
traded Mar 23, 2026
+2dSEC FORM 4

Evidence

29
SM
Skelton Laurence MatthewChief Commercial Officer
VERAVera Therapeutics, Inc.
Open-market sale
SELL$66K
1,582 sh
Feb 23, 2026Feb 25, 2026
traded Feb 23, 2026
+2dSEC FORM 4

Evidence

29
BR
Brenner RobertChief Medical Officer
VERAVera Therapeutics, Inc.
Open-market sale
SELL$90K
2,151 sh
Feb 23, 2026Feb 25, 2026
traded Feb 23, 2026
+2dSEC FORM 4

Evidence

21
BR
Brenner RobertChief Medical Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
25.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
SM
Skelton Laurence MatthewChief Commercial Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
40.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
SM
Skelton Laurence MatthewChief Commercial Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
20.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
BR
Brenner RobertChief Medical Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
50.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
GS
Grant SeanCHIEF FINANCIAL OFFICER
VERAVera Therapeutics, Inc.
Grant or award
A—
25.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
GS
Grant SeanCHIEF FINANCIAL OFFICER
VERAVera Therapeutics, Inc.
Grant or award
A—
50.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

13
YR
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
VERAVera Therapeutics, Inc.
Grant or award
A—
10.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
YR
Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR
VERAVera Therapeutics, Inc.
Grant or award
A—
20.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

17
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Grant or award
A—
68.8K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
FM
Fordyce MarshallDirector, PRESIDENT AND CEO
VERAVera Therapeutics, Inc.
Grant or award
A—
137.5K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

21
TD
Turner William D.Chief Regulatory Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
25.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

9
TD
Turner William D.Chief Regulatory Officer
VERAVera Therapeutics, Inc.
Grant or award
A—
50.0K sh
Feb 4, 2026Feb 6, 2026
traded Feb 4, 2026
+2dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Skelton Laurence MatthewChief Commercial Officer · Feb 6, 2026
  • ← Insider ofevidence
    Young Joseph RSVP, FINANCE, CHIEF ACCT OFFCR · Feb 6, 2026
  • ← Insider ofevidence
    Fordyce MarshallDirector, PRESIDENT AND CEO · Feb 6, 2026
  • ← Insider ofevidence
    Grant SeanCHIEF FINANCIAL OFFICER · Feb 6, 2026
  • ← Insider ofevidence
    Brenner RobertChief Medical Officer · Feb 6, 2026